| 2026-05-16 |
复牌提示：
2026-05-15 14:32:36 停牌，复牌日期 2026-05-15 14:37:36
|
| 2026-05-14 |
详情>>
业绩披露：
2026年一季报每股收益0.37美元,归母净利润198.40万美元,同比去年增长190.31%
|
| 2026-04-28 |
股东大会：
将于2026-06-15召开股东大会
会议内容 ▼▲
- 1.Election of Directors. To elect the Class II directors listed in the accompanying proxy statement to serve a three-year term expiring at the 2029 annual meeting of stockholders and until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal (“Proposal One”).
2.Appointment of Company’s Auditors. To ratify the appointment of Crowe LLP as the independent registered public accounting firm of HCW Biologics Inc. for the fiscal year ending December 31, 2026 (“Proposal Two”).
3.Reverse Stock Split to Maintain Nasdaq Listing. To approve an amendment to the Company’s certificate of incorporation on or before the one year anniversary of the Annual Meeting, to implement one or more reverse stock splits of the outstanding shares of the Company’s common stock, par value $0.0001 per share (our “Common Stock”) (as necessary to maintain a listing of our Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”)) in an aggregate range from one-for-five (1:5) up to one-for-twenty (1:20). (“Proposal Three”);
4.Issuance of Shares Upon Exercise of Common Warrants. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock upon exercise of up to 2,477,292 Common Stock Purchase Warrants (the “Common Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated February 17, 2026, entered into in connection with the Company’s follow-on public offering of Units, consisting of one share of Common Stock purchased for $0.6055 and one Common Warrant which may be exercised to purchase one share of Common Stock for $0.6055 per share. The Company is obliged to submit this proposal for a stockholders’ vote every 60 days, until passed. (“Proposal Four”);
5.Warrants Repricing Proposal. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the repricing of certain warrants issued on November 20, 2025 to purchase up to 3,020,410 shares of our Common Stock pursuant to that certain Existing Warrants Amendment Agreement, dated February 17, 2026, to reduce the exercise price of the Existing Warrants to $0.6055 per share, and to approve the issuance of shares of our Common Stock upon exercise of the Existing Warrants as so amended. The Company is obliged to submit this proposal for a stockholders’ vote every 60 days, until passed or until such warrants are no longer outstanding. (“Proposal Five”);
|
| 2026-03-31 |
详情>>
股本变动：
变动后总股本673.41万股
|
| 2026-03-31 |
详情>>
业绩披露：
2025年年报每股收益-10.63美元,归母净利润-2229.87万美元,同比去年增长25.73%
|
| 2026-03-13 |
股东大会：
将于2026-04-27召开股东大会
会议内容 ▼▲
- 1.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock upon exercise of up to 2,477,292 Common Stock Purchase Warrants (the “Common Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated February 17, 2026 (the “SPA”), entered into in connection with the Company’s follow-on public offering of Units (the “Offering”), which Offering was conducted pursuant to a registration statement (the “Registration Statement”) declared effective by the Securities and Exchange Commission on February 17, 2026 and closed on February 19, 2026, as previously disclosed in the Company’s Current Report on Form 8-K filed on February 19, 2026, each Unit consisting of (i) one share of Common Stock or one Pre-Funded Warrant to purchase one share of Common Stock and (ii) one Common Warrant, with such Common Warrants exercisable only upon receipt of stockholder approval and having an exercise price equal to 100% of the public offering price per Unit, and such additional terms and conditions of the Common Warrants not materially inconsistent with the foregoing as our Board may hereafter approve;
2.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the repricing of certain warrants issued on November 20, 2025 to purchase up to 3,020,410 shares of our Common Stock (the “Prior Warrants”) pursuant to that certain Existing Warrants Amendment Agreement, dated February 17, 2026, entered into in connection with the Offering conducted pursuant to the Registration Statement (as disclosed in the Company’s Current Report on Form 8-K filed on February 19, 2026), to reduce the exercise price of the Prior Warrants from $2.41 per share to $0.6055 per share, and to approve the issuance of shares of our Common Stock upon exercise of the Prior Warrants as so amended, and such additional terms and conditions of such amendment not materially inconsistent with the foregoing as our Board may hereafter approve;
3.To transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.
4.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the repricing of certain warrants issued on November 20, 2025 to purchase up to 3,020,410 shares of our Common Stock (the “Prior Warrants”) pursuant to that certain Existing Warrants Amendment Agreement, dated February 17, 2026, entered into in connection with the Offering conducted pursuant to the Registration Statement (as disclosed in the Company’s Current Report on Form 8-K filed on February 19, 2026), to reduce the exercise price of the Prior Warrants from $2.41 per share to $0.6055 per share, and to approve the issuance of shares of our Common Stock upon exercise of the Prior Warrants as so amended, and such additional terms and conditions of such amendment not materially inconsistent with the foregoing as our Board may hereafter approve.
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-11.34美元,归母净利润-1883.27万美元,同比去年增长29.33%
|
| 2025-08-18 |
详情>>
业绩披露：
2025年中报每股收益-9.86美元,归母净利润-1427.84万美元,同比去年增长37.23%
|
| 2025-05-16 |
详情>>
内部人交易：
Winer Gary M等共交易3笔
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.05美元,归母净利润-219.69万美元,同比去年增长70.58%
|
| 2025-04-28 |
股东大会：
将于2025-06-17召开股东大会
会议内容 ▼▲
- 1.Elect the Class I directors listed in the accompanying proxy statement to serve a three-year term expiring at the 2028 annual meeting of stockholders and until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
2.Ratify the appointment of Crowe LLP as the independent registered public accounting firm of HCW Biologics Inc. for the fiscal year ending December 31, 2025.
3.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2025-04-10 |
详情>>
拆分方案：
每40.0000合并分成1.0000股
|
| 2025-03-28 |
详情>>
业绩披露：
2024年年报每股收益-0.77美元,归母净利润-3002.38万美元,同比去年增长-20.12%
|
| 2025-02-21 |
股东大会：
将于2025-03-31召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Certificate of Incorporation on or before the one (1) year anniversary of the Special Meeting, to implement one or more reverse stock splits of the outstanding shares of the Company’s common stock, par value $0.0001 per share (our “Common Stock”) (as necessary to maintain a listing of our common stock on The Nasdaq Stock Market LLC (“Nasdaq”)) in an aggregate range from one-for-twenty (1:20) up to one-for-fifty (1:50), or anywhere between (the “Reverse Stock Split”), all as determined in the sole discretion of our Board of Directors (our “Board”) (the “Reverse Stock Split Proposal”) (“Proposal One”);
2.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of our Common Stock, or such lesser number of shares as our Board determines, pursuant to that certain Equity Purchase Agreement, dated February 20, 2025 (the “Purchase Agreement”) set forth on Appendix A attached hereto and that certain Registration Rights Agreement, dated February 20, 2025 (the “Rights Agreement”) set forth on Appendix A hereto, entered into in connection with an equity line of credit with Square Gate Capital Master Fund, LLC – Series 4 (the “ELOC Proposal”) (“Proposal Two”);
3.To approve, for purposes of complying with Nasdaq Listing Rules 5635(c) and 5635(d), the issuance of shares of our Common Stock upon conversion of up to $6,905,000 of principal amount of Senior Secured Notes issued by the Company to certain investors therein, including certain officers, directors and stockholders of the Company (the “Noteholders”), pursuant to that certain Amended and Restated Senior Secured Note Purchase Agreement dated July 2, 2024, as amended by the First Amendment to Amended and Restated Senior Secured Note Purchase Agreement dated September 30, 2024, and as it may be further amended in accordance with the Principal Terms for Conversion Amendment, which has been approved by our Board and the Noteholders and set forth on Appendix B attached hereto (the “Principal Terms”) and such additional terms and conditions not materially inconsistent with such Principal Terms for Conversion as our Board may hereafter approve (the “Note Conversion Proposal”) (“Proposal Three”).
4.To transact such other business as may properly come before the Special Meeting or any adjournments or postponements thereof.
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.71美元,归母净利润-2665.05万美元,同比去年增长-86.19%
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.61美元,归母净利润-2274.83万美元,同比去年增长-142.65%
|
| 2024-05-15 |
详情>>
业绩披露：
2023年年报每股收益-0.7美元,归母净利润-2499.43万美元,同比去年增长-67.74%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.2美元,归母净利润-746.81万美元,同比去年增长-47.28%
|
| 2024-04-26 |
股东大会：
将于2024-06-14召开股东大会
会议内容 ▼▲
- 1.Elect the Class III director listed in the accompanying proxy statement to serve a three-year term expiring at the 2027 annual meeting of stockholders and until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
2.Ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm of HCW Biologics Inc. for the fiscal year ending December 31, 2024.
3.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2023-04-27 |
股东大会：
将于2023-06-13召开股东大会
会议内容 ▼▲
- 1.Elect the two Class II directors listed in the accompanying proxy statement, each to serve a three-year term expiring at the 2026 annual meeting of stockholders and until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
2.Ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm of HCW Biologics Inc. for the fiscal year ending December 31, 2023.
3.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2022-04-25 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.Elect the two Class I directors listed in the accompanying proxy statement,each to serve a three-year term expiring at the 2025 annual meeting of stockholders and until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation,disqualification or removal.
2.Ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm of HCW Biologics Inc. for the fiscal year ending December 31, 2022.
3.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|